Introduction
In literature retrieval data searches may be insufficient' 2 and often have to be supplemented by scanning the reference lists. This may lead to a biased selection of articles, particularly if the reference lists reflect the authors' prejudices. The existence of a one sided reference bias was suggested by Sackett in 1979 concerning two articles on the inheritance of hypertension,3 but it seems not to have been shown statistically.
Reports of drug trials are an excellent opportunity for studying this possible bias: they may be numerous and the outcome can often be easily classified. This study examined trials of non-steroidal anti-inflammatory drugs. figure) . This low level of citation was also found when only the drugs which the authors had studied were considered. Reference to other trials with the same new and control drug was omitted in 38% of articles in which it would have been possible. The omissions were of the same order ofmagnitude when a three year limit for the availability ofthe references was used.
Reference bias- Table I shows the analysis of the remaining 111 articles. The number of articles in which the available references were exclusively positive or not positie isshown separately, since no bias was possible in these cases. There was a significant bias towards a positive selection ofreferences on the new drug, both for any language (p<0-01) and for references in English (p<005). Foranylanguage, whenthe 35 articlesinwhichbiaswasimpossible and the 10 with a neutral selection were ignored then 44 of the remaining 66 articles (67%; 95% confidence interval 54% to 78%) had an overrepresentation of references to trials with a positive outcome for the new drug. With a three year limit for the references the bias was also apparent (p<0-01 for both analyses). The bias was not caused by overrepresentation of highly cited journals among the articles with a positive selection of references (table II) . 
Discussion
This study has shown a high frequency of multiple publication and reference bias. Multiple publication was sometimes difficult to detect: the number of authors might differ; the first author might vary; the title might be different; and the name of the institution might be omitted. If multiple publication is not detected it may cause problems in any pooled analysis of trials (meta-analysis) or mislead the reader of the individual article. In fact, five articles referred to multiple publications by others as if these concerned separate trials. Multiple publication Was often due to company sponsored symposia, published as supplements, and the motive was not apparently to have versions in different languages, since these were different in only 12 of the 44 articles. Nevertheless, multiple publication was also frequently seen in current journals. One trial was published twice in the same journal, with 104 patients initially and six patients added five years later, without any reference to the first article.
The larger the number of possible references the less should be the impact of being unaware of a single reference. Thus any reference bias should be at its greatest when the authors have many articles to choose from. This was exactly the case: the bias for eight or more possible references was statistically significant (p<001, fewer references are possible in any restricted analysis while, correspondingly, the number of articles where no bias is possible will be higher. A manual search of journals might have identified some further articles, but I did not know which journals to look in. The 200 articles were published in 63 journals or journal supplements, as well as in a few symposia in book form. Even so, given that I made great efforts to secure as complete a sample as possible, using standard methods, I believe that any undetected articles would have been unlikely to affect the results of this study. - A decision to refer to a particular trial may well depend on the quality of the methods used, and hence I analysed only double blind trials. (Such studies are usually also randomised, thus fulfilling what are probably the two most important methodological criteria for clinical trials.) Surprisingly, many articles had no references to other double blind trials with the same drugs. Thus, the reference pattern was somewhat irrelevant, since the aim of these trials, all with ai. active control drug, was pragmatic, trying to solve the question of which drug should be preferred. 6 The trials that were least cited in the reference lists were not published in journals or books that are difficult to obtain either in the library or through a Medline search, nor did they concern unfamiliar drugs. In fact, the reference bias was caused mainly by a biased selection of references on indomethacin, the most common control drug used in the study. Reference was made only twice to trials on controls not represented in the sample. A bias in the initial classification of drugs as positive or not positive is unlikely, since it would have been impossible to foresee what given judgments would have led to in the analysis, carried out months later.
In conclusion, therefore, the reference bias shown in this study seems to be real. Such a finding has important implications, since there is no reason to believe that rheumatologists are more biased than others in selecting references. A reader tracing the literature on any new drug using the reference lists given in the articles might risk obtaining a biased sample. Reference bias has another serious implication: it may render the conclusion of the individual article less reliable. Is So long as statistical significance is used as a major criterion of acceptability for publication the published results of medical research will contain a high proportion of false positive results. Thus quantitative estimates of treatment effects taken from published work cannot be regarded as free from bias. There are established methods to calculate the power of a study, which is the probability ofdetecting a specified, important difference using a test with a set significance level. The interpretation of statistical power is satisfactory only when it is calculated with values specified at the design stage ofthe study. The proper method to assess the adequacy of the sample size is by peer review of values specified in the protocol. If this is done the significance level eventually attained is no longer relevant to selection for publication.
Importance of sample size Manuscripts submitted to medical journals often contain serious statistical faults.' Various steps have been taken to remedy this,
